Differential AKT dependency displayed by mouse models of BRAF V600E-Initiated melanoma

Journal of Clinical Investigation

Volumn 123, Issue 12, 2013, Pages 5104-5118

  Durban, Victoria Marsh ^a   Deuker, Marian M ^a   Bosenberg, Marcus W ^b   Phillips, Wayne ^c   McMahon, Martin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFIMOXIFENE; B RAF KINASE; BUPARLISIB; LGX 818; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PICTILISIB; PROTEIN KINASE B; PROTEIN S6; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN CARCINOGENESIS; TISSUE CULTURE;

ANIMALS; APOPTOSIS; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MUTATION; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR CELLS, CULTURED;

EID: 84890062777     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69619     Document Type: Article

References (65)

1. Chin L, Merlino G, DePinho RA. Malignant melanoma: modern black plague and genetic black box. Genes Dev. 1998;12(22):3467-3481
2. Jemal A, et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)- associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175-201
3. Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-819
4. Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703
5. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954
6. Pollock PM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19-20
7. Bennett DC. Human melanocyte senescence and melanoma susceptibility genes. Oncogene. 2003; 22(20):3063-3069
8. Michaloglou C, et al. BRAFE600-associated senescence- like cell cycle arrest of human naevi. Nature. 2005;436(7051):720-724
9. Dankort D, et al. BRAF(V600E) cooperates with PTEN loss to induce metastatic melanoma. Nat Genet. 2009;41(5):544-552
10. Dhomen N, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009; 15(4):294-303
11. Goel VK, et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene. 2009;28(23):2289-2298
12. Peeper DS. Oncogene-induced senescence and melanoma: where do we stand? Pigment Cell Melanoma Res. 2011;24(6):1107-1111
13. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol. 2006;126(1):154-160
14. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res. 2006; 12(7 pt 2):2301s-2307s
15. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 2011;24(5):879-897
16. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273(22):13375-13378
17. Campbell IG, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004; 64(21):7678-7681
18. Samuels Y, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304(5670):554
19. Omholt K, Krockel D, Ringborg U, Hansson J. Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res. 2006;16(2):197-200
20. Hodis E, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-263
21. Shen WH, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007; 128(1):157-170
22. Song MS, et al. Nuclear PTEN regulates the APCCDH1 tumor-suppressive complex in a phosphataseindependent manner. Cell. 2011;144(2):187-199
23. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 2003; 22(20):3113-3122
24. Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23(4):575-587
25. Rankin SL, Guy CS, Mearow KM. PTEN downregulates p75NTR expression by decreasing DNAbinding activity of Sp1. Biochem Biophys Res Commun. 2009;379(3):721-725
26. Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V, Bosenberg MW. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res. 2010;70(1):388-397
27. Damsky WE, et al. β-Catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell. 2011;20(6):741-754
28. V600E-positive melanoma. Presented at: 245th American Chemical Society National Meeting and Exposition; April 7-11, 2013; New Orleans, Lousiana, USA
29. Drahl C. LGX818, made to fight melanoma. Chem Engineer News. 2013;91(16):14
30. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011;8(7):426-433
31. Smalley KS, et al. Meeting report from the 2011 international melanoma congress, Tampa, Florida. Pigment Cell Melanoma Res. 2011;25(1):E1-E11
32. Kinross KM, et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest. 2012; 122(2):553-557
33. Trotman LC, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1(3):E59
34. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAF(V600E)-induced lung tumors. Genes Dev. 2007; 21(4):379-384
35. Bosenberg M, et al. Characterization of melanocyte- specific inducible Cre recombinase transgenic mice. Genesis. 2006;44(5):262-267
36. Nogueira C, et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene. 2010;29(47):6222-6232
37. Mason VL. American association for cancer research - 101st annual meeting - investigating new therapeutic candidates: part 2. IDrugs. 2010;13(6):360-362
38. Stephens L, Hawkins P. Signalling via class IA PI3Ks. Adv Enzyme Regul. 2010;51(1):27-36
39. Hirai H, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956-1967
40. Aguirre AJ, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003; 17(24):3112-3126
41. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther. 2006;5(5):1136-1144
42. Haass NK, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res. 2008; 14(1):230-239
43. Solit DB, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358-362
44. Laquerre S, et al. Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation. Poster presented at: AACRNCI- EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 15-19, 2009 Boston, Massachusetts, USA; 2009; 8(12):B88
45. Morris EJ, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013; 3(7):742-750
46. Folkes AJ, et al. The identification of 2-(1H-indazol- 4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)- 4-morpholin-4-yl-thieno[3,2-d] pyrimidine (GDC- 0941) as a potent, selective, orally bioavailable inhibitor of class 1 PI3 kinase for the treatment of cancer. J Med Chem. 2008;51(18):5522- 5532
47. Maira SM, et al. Identification and characterization of NVP-BKM120, an orally available panclass 1 PI3-kinase inhibitor. Mol Cancer Ther. 2012; 11(2):317-328
48. Heerding DA, et al. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl) -1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}1H-imidazo[4,5-c]pyridin-4-yl) -2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem. 2008; 51(18):5663-5679
49. Rhodes N, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 2008;68(7):2366-2374
50. Brachmann SM, et al. Characterization of the mechanism of action of the pan class 1 PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012; 11(8):1747-1757
51. Cartlidge RA, et al. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res. 2008;21(5):534-544
52. Chou TC, Talalay P. Quantitative analysis of doseeffect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55
53. Brachmann SM, et al. Characterization of the mechanism of action of the pan class 1 PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012;11(8):1747-1757
54. Chin L, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 1997; 11(21):2822-2834
55. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev. 2005; 24(1):165-183
56. Pollock PM, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet. 2003;34(1):108-112
57. Mooi WJ, Peeper DS. Oncogene-induced cell senescence - halting on the road to cancer. N Engl J Med. 2006;355(10):1037-1046
58. Kaplon J, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature. 2013;498(7452):109-112
59. Vredeveld LC, et al. Abrogation of BRAFV600Einduced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012; 26(10):1055-1069
60. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res. 2011;71(11):3863-3871
61. Trejo CL, et al. Mutationally activated PIK3CAH1047R cooperates with BRAFV600E in lung cancer progression [published online ahead of print September 9, 2013]. Cancer Res. doi:canres.0681.2013
62. Kim JE, et al. Comparison of growth factor signaling pathway utilisation in cultured normal melanocytes and melanoma cell lines. BMC Cancer. 2012;12:141
63. Vasudevan KM, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009;16(1):21-32
64. Zaidi MR, et al. Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature. 2011;469(7331):548-553
65. Wolnicka-Glubisz A, King W, Noonan FP. SCA- 1+ cells with an adipocyte phenotype in neonatal mouse skin. J Invest Dermatol. 2005;125(2):383-385